MedicalResearch.com Interview with:
[caption id="attachment_60633" align="alignleft" width="150"]
Dr. Guttman-Yassky[/caption]
Emma Guttman-Yassky, M.D., PhD,
Lead investigator of this study
Waldman Professor and
System Chair
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai, NY
MedicalResearch.com: What is the background for this study?
Response: The idea to test how spacing out treatment or even stopping it affects treatment responses once patients are well controlled. Lebrikizumab it is a potent biologic agent with a relatively long-lasting effect.
